Fed’s Powell opens door to potential rate cuts at Jackson Hole
Jean F. Holloway, Senior Vice President and General Counsel at Artivion, Inc. (NYSE:AORT), recently executed a transaction involving the company’s common stock. On March 6, 2025, Holloway sold 2,124 shares at a price of $24.80 per share, totaling $52,685. The transaction occurred above the current trading price of $23.50, with the stock showing significant volatility according to InvestingPro data. This transaction was conducted to cover tax withholding obligations following the vesting of performance stock units. Following the sale, Holloway holds 196,112 shares of Artivion.
Additionally, Holloway acquired 25,493 shares of common stock on the same date, as part of a performance stock unit grant from February 2024. These shares were issued at no cost, with further vesting scheduled for 2026 and 2027, contingent on continued employment.
In other recent news, Artivion Inc. reported its fourth-quarter 2024 earnings, revealing a revenue of $97.3 million, which fell short of the forecasted $100.82 million. This shortfall was largely attributed to a cybersecurity breach that impacted sales by approximately $4.5 million. Despite the revenue miss, Artivion’s adjusted EBITDA for the quarter was $17.6 million, surpassing expectations. Analysts from Stifel, Needham, and JMP Securities responded to the earnings report with mixed adjustments to Artivion’s stock price target, citing the impact of the cyber incident. Stifel lowered its price target to $30 from $33, while Needham adjusted theirs to $32 from $34, both maintaining a Buy rating. JMP Securities, however, maintained its price target at $33 and a Market Outperform rating.
Artivion’s management has forecasted 2025 revenue to range between $420 million and $435 million, representing a 10-14% growth. The company also anticipates adjusted EBITDA between $83 million and $91 million for 2025, which is more favorable compared to prior projections. Artivion expects the effects of the cybersecurity incident to extend into the first quarter of 2025, with projected revenues between $94 million and $98 million, below previous estimates. However, they anticipate a rebound in sales growth throughout the year. The company reported strong product performances in its On-X, stent graft, and BioGlue lines, though its Preservation Services experienced a decline. Despite these challenges, analysts at Needham expect a robust recovery for Artivion throughout 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.